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Hepatosplenic T-cell 
lymphoma following infliximab 
therapy for Crohn’s disease
Daniel C Burger and Timothy H J Florin
TO THE EDITOR: We read with great
interest Drini and colleagues’ recent report
o f  hepatosplenic  T-cel l  lymphoma
(HSTCL) associated with inflammatory
bowel disease.1 The occurrence of this rare
lymphoma is partly driving a move away
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from the use of combination thiopurine
and anti-tumour necrosis factor alpha
therapy. It is important to recognise that
risk of HSTCL is not only associated with
exposure to thiopurine drugs with or with-
out infliximab. It is associated with
immunocompromise in general, and also
occurs de novo. Explaining relative risks to
patients is never easy and needs to be
balanced with the need for treatment in
properly selected patients.
Contrary to a comment by Drini and
colleagues, HSTCL has been reported in
association with exposure to adalimumab,
another anti-tumour necrosis factor alpha
agent.2 Two of these cases occurred in
patients with prior exposure to thiopurines
and infliximab, and the third occurred in a
patient with rheumatoid arthritis who was
not exposed to thiopurine or infliximab.
There has been a recent spate of reports of
HSTCL in patients with inflammatory
bowel disease treated with immunomodu-
lator therapy, but most HSTCL appears to
occur in patients without exposure to
immunosuppressants.3 Also, although
cases predominantly occur in young men
(under 22 years), HSTCL is not limited to
the paediatric age group.3,4 The presenta-
tion also occurs in females, including dur-
ing pregnancy.
More generally, in patients with inflam-
matory bowel disease, treatment with thio-
purines appears to increase the risk of
lymphoma two- to fourfold.5 Assuming a
fourfold increase in risk, this translates
into one additional lymphoma per year for
every 4357 patients treated with thiopur-
ines at age 20–29 years.5 This should be
compared with the lifetime attributable
risk of death from any cancer due to a
single abdominal computed tomography
scan performed at the age of 20, which is
in the order of 1 : 2000.6 Currently, it is
difficult to completely disentangle the
many different factors — including patient
age; severity, duration and course of dis-
ease;7 type of immunosuppression; and
exposure to radiation — when considering
the risk of lymphoma in inflammatory
bowel disease. However, in many patients
with severe disease, this risk appears to be
outweighed by the benefits of adequate
medical control.
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